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CC BY-NC-ND license (http://creativRetroperitoneal lymphangioma is extremely rare. Although these neoplasms are benign, they
can grow progressively with subsequent compression and infiltration of the adjacent struc-
tures. Surgical excision is demanding when the lesion surrounds vital structures and it is gener-
ally fraught with a high recurrence and morbidity rate. We report the case of a huge
retroperitoneal lymphangioma in a newborn treated successfully with intracystic injection
of OK-432.
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by-nc-nd/4.0/).1. Introduction
Lymphangiomas are congenital anomalies of the lymphatic
system. Cystic lymphangiomas can occur in any location in
which lymphatics are normally found, but most are located
in the head and neck (75%) and the axillary region (20%).1urgery Unit, Policlinico “A.
0168 Rome, Italy.
ero.it (C. Olivieri).
013.06.011
Pediatric Association. Published
ecommons.org/licenses/by-nc-ndRetroperitoneal lymphangiomas account for nearly 1% of
all lymphangiomas.
Large but localized lymphangiomas can be excised
completely, although the surgical treatment of diffuse and
multiple lesions is extremely difficult and is associated with
a high morbidity and recurrence rate.2,3 The intracystic
injection of a sclerosing agent is considered appropriate for
the treatment of surgically unresectable lesions and, ac-
cording to the wide experience reported by Ogita et al,3
OK-432 is the preferred sclerosing agent. To the best of
our knowledge, only two cases of successful sclerosing (OK-
432) treatment of retroperitoneal lymphangioma have beenby Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
OK-432 therapy for retroperitoneal lymphangioma 241reported in the literature.4,5 Herein, we report the case of
an infant with prenatal diagnosis of a huge right retroper-
itoneal lymphangioma who was successfully treated with a
single injection of OK-432.
2. Case Report
A 36-year-old woman, gravida 1, para 0, was referred to our
hospital at 24 weeks’ gestation for evaluation of a fetal
intra-abdominal cystic mass. Ultrasound examination at 24
weeks’ gestation showed a mass (37  26 mm) in the right
side of the fetal abdomen, extending from the lower kidney
pole down to the bladder. Magnetic resonance imaging
(MRI), performed at 25 weeks’ gestation, revealed a mul-
tilocular right retroperitoneal mass (53  47  37 mm) with
medial displacement of the ipsilateral kidney (Figure 1).
Neither fat nor calcifications in the tumor were evident at
MRI. These findings were compatible with a lymphangioma.
At 38 weeks’ gestation, a 4200 g boy was born by an
elective cesarean section following an uneventful preg-
nancy. On physical examination the abdomen was soft and
the documented mass was not easily palpated. No other
abnormalities were detected. On Day 5, abdominal ultra-
sonography confirmed the presence, characteristics and
limits of the large retroperitoneal multiseptated cystic
mass. In order to better define its relationship with the
renal vessels and the inferior vena cava, an MRI was per-
formed on Day 8 (Figure 2).
The multiloculated lesion extended from the inferior
surface of the liver down to the right iliac fossa, measuring
80  60  50 mm; the right kidney was encircled and dis-
placed medially. Posteriorly the lesion infiltrated the
posterolateral abdominal wall, involving the latissimus
dorsi muscle.
At 8 weeks, the patient underwent sclerotherapy with
OK-432. Using ultrasound guidance, we injected 0.1 mg of
OK-432 diluted in 10 mL of saline after aspiration of the
same volume of straw colored clear fluid from two super-
ficial cysts on the right flank.
One and 4 months after the treatment abdominal ul-
trasound examination was performed: no mass was evident.
At 12 months of follow-up, the patient is asymptomatic.
3. Discussion
Lymphangiomas are rare benign cystic tumors of the
lymphatic system. Abdominal lymphangiomas account forTable 1 Cases of retroperitoneal lymphangiomas treated with
Case no. Author Sclerosing
agent
Starting
treatmen
1 Rothenberg et al14 Doxycycline 13 y
2 Shankar et al6 Tetracycline 4 y
3 Uchida et al4 OK-432 4 wks
4 Gu¨venc et al5 OK-432 6 wks
5 Present case OK-432 8 wksless than 10% of all these congenital lesions. Retroperito-
neal lymphangiomas are even less common: 50% of them
are present at birth and 90% are diagnosed within the first 2
years.6
Surgical excision is the preferred treatment for lym-
phangiomas, to avoid rapid growth, superinfection,
rupture, or bleeding that can require an emergent
laparotomy.7
Although surgery is considered to be the treatment of
choice, complete surgical removal may not be possible
when lesions surrounding great vessels and vital nerves are
present because of the inherent high risk of damaging the
adjacent structures. The reported complication rates
following operative intervention for lymphangiomas range
from 12% to 33%.8,9
A subtotal excision, with preservation of vital structures,
is reported to be unsatisfactory with a rate of recurrence of
12e53%.10
In 1987, Ogita reported good results in patients with
unresectable lymphangiomas after intracystic injection of
OK-432, a sclerosing agent derived from a strain of Strep-
tococcus pyogenes.11 In fact, the use of OK-432 has proved
safe and effective for treatment of lymphangiomas in
children yielding a complete resolution of the lesion in 92%
of cystic lymphangiomas.12 The injection of OK-432 causes
the induction of neutrophils and macrophages, responsible
for an increased production of tumor necrosis factor (TNF).
The increased level of TNF is considered to play an impor-
tant role in the regression of lymphangiomas.13 The local
inflammation does not damage the overlying skin and does
not lead to scar formation, thus not impairing a possible
surgical therapy whenever sclerotherapy has proved
unsuccessful.
Although the sclerosing treatment with OK-432 has
become a well-known approach for cystic lymphangiomas,
its application is confined to superficial and accessible le-
sions, such as those in the limbs or head and neck region.
So far, four cases of retroperitoneal lymphangiomas
treated with sclerotherapy have been reported (Table
1).4e6,14 Of these, only two cases have been treated with
OK-432;4,5 in one case as a first line treatment and in the
other as a rescue therapy after failure of a former marsu-
pialization followed by a partial resection.
In our case, considering the huge size of the lesion and
its close relationships with the right kidney and ureter, a
complete resection was deemed difficult and risky, so
ultrasound guided percutaneous intracystic injection of
OK-432 was decided upon. This approach was possible duesclerotherapy.
t
Associated treatments No. of
injections
Outcome
Partial excision 1 Resolved
Percutaneous catheter
drainage
1 Resolved
No 2 Resolved
Marsupialization, Limited
surgical excision
1 Resolved
No 1 Resolved
Figure 1 (A) Axial T2-weightedHASTEMR image shows a right retroperitoneal cysticmasswith septations displacing thebowel loops
and no sign of infiltration. (B) Sagittal T2-weighted MR image shows the lesion surrounds the right kidney without infiltrating it.
242 C. Olivieri et alto the presence of two superficial cysts on the right flank,
documented on ultrasound examination. OK-432 was
injected at a dose of 0.1 mg, according to the method of
Ogita et al: 0.1 mg of OK-432 in 10 mL of physiologic sa-
line and the volume of aspirated fluid replaced with anFigure 2 (A) Axial and (B) coronal T2-weighted MR images on Day
is hyperintense and shows multiple internal septae. The right kidn
Figure 3 (A) Pre-treatment longitudinal US scan shows a cystic le
Post-treatment longitudinal US scan shows no evidence of the cystequal volume of OK-432 solution.12 One month after
the sclerosing treatment, abdominal ultrasound exami-
nation showed a complete disappearance of the lym-
phangioma and no damage occurred to the overlying skin
(Figure 3).8 showing a retroperitoneal multiocular cystic mass. The lesion
ey (arrow) is displaced anteriorly.
sion with an internal septum, anteriorly to the right kidney. (B)
ic mass.
OK-432 therapy for retroperitoneal lymphangioma 243A case of retroperitoneal lymphangioma treated success-
fully with a single injection of OK-432 has not been previously
reported in the literature. Actually, unlike to the two previ-
ous cases, the unique feature of our case is the rapid reso-
lution of the lesion after the first sclerosing treatment,
without resorting to a second intracystic injection of OK-432
or a surgical treatment to reduce the size of the lesion, as
reported by Uchida et al4 and Gu¨venc et al5, respectively.
In all three cases the cystic mass was retroperitoneal
and resolved with OK-432. Gu¨venc et al5 performed an
intralesional injection of OK-432 intraoperatively after a
limited resection; whereas, in the case reported by Uchida
et al4 the site of injection was the flank, similar to our case,
but two injections were necessary to obtain complete res-
olution of the lesion.
Laparoscopy can provide a less invasive approach than
laparotomy in resection of abdominal lymphangiomas and
its inherent magnification can certainly aid in facilitating
dissection.15 Moreover, in those cases in which the lesion is
unresectable or when percutaneous approach is not
feasible, laparoscopy could effectively enhance sclero-
therapy aiding in localizing and injecting the lesions.
However, if the lesion is not reduced within 3e6 weeks
after the first treatment, a second injection can be
considered before performing a surgical approach.
The present case suggests that injection of OK-432 can
be useful for the retroperitoneal lymphangiomas, avoiding
surgery and the risks correlated with the surgical approach.Conflicts of interest statement
Claudio Olivieri and co-authors have no conflict of interest
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